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Background: Daptomycin is an alternative option for the treatment of catheter-related bloodstream-infections caused
by methicillin-resistant Staphylococcus aureus. This study reports a case of a daptomycin and methicillin-resistant
Staphylococcus aureus isolate recovered from the blood of a Brazilian patient undergoing hemodialysis.
Case presentation: A 64-year-old white male patient suffering from diabetes mellitus, systolic hypertension, heart
disease with a coronary stent, obesity and chronic renal failure and on use of permcath catheter developed a
catheter-related bloodstream-infection by a daptomycin-methicillin-resistant Staphylococcus aureus isolate after one
month of daptomycin therapy. The isolate was identified as the SCCmec II/USA100/sequence type 5 lineage by
molecular techniques.
Conclusions: In this work we described a Brazilian patient with bloodstream infection caused by a daptomycin and
methicillin-resistant Staphylococcus aureus belonging to the lineage USA100/sequence type 5. Our case highlights the
careful management of bloodstream infections and the importance of the judicious use of antimicrobials due the
possibility of daptomycin-resistance developing among S. aureus isolates, especially in patients under hemodialysis,
which are frequently exposed to vancomycin and daptomycin therapy.
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Methicillin-resistant Staphylococcus aureus (MRSA) is
one of the most important causes of catheter-related
bloodstream-infections (CRBSI) among hemodialysis
patients [1,2] and daptomycin is an alternative option
for the treatment [3]. In Brazil, there is only one report
describing two isolates of daptomycin-resistant S. aur-
eus; however no information was given concerning the
clinical conditions of the patients [4]. This study reports
the case of a daptomycin-resistant MRSA isolate recov-
ered from the blood of a Brazilian patient undergoing* Correspondence: santoskrn@micro.ufrj.br
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lar characteristics of the isolate are described.Case presentation
A 64-year-old white male, resident in Rio de Janeiro, has
been managing our hospital due to insulin dependent dia-
betes mellitus, arterial hypertension, chronic coronary dis-
ease and renal failure. In August of 2011, he began
hemodialysis in our hospital as his renal glomerular func-
tion became worse. In March 2012, one month after
implanting a permcath catheter he came for the emer-
gency department with signs of infection to elucidate. The
results of the microscopic examination of urinary sedi-
ment showed 15 to 20 white blood cells (WBC), and so
cephalexin was begun to treat a possible urinary infection.
However, three days after the antibiotic therapy was beguntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Minimum inhibitory concentrations (MIC) of
daptomycin of 30 methicillin-resistant S. aureus isolates
according to MIC of vancomycin presented by these isolates
MIC of vancomycin
(N° of isolates)
MIC of daptomycin No (%) of isolates
0.5 1 2 4
0.5 (1) 1 (100) 0 0 0
1 (13) 2 (15.4) 7 (53.8) 3 (23.1) 1 (7.7)
2 (12) 0 7 (58.3) 4 (3.3) 1 (8.4)
4 (4) 1 (25) 1 (25) 1 (25) 1 (25)
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The patient returned with signs of systemic inflamma-
tory response syndrome. A clinical examination of the
patient showed an inflammation at the insertion site of
the hemodialysis catheter. The patient was admitted in
our critical care unit on 7 March 2012 with suspicion of
CRBSI. The catheter was removed and another was im-
planted in his right femoral vein. Two samples of per-
ipheral blood were sent for culture and empiric therapy
with vancomycin and piperacillin-tazobactam was initi-
ated within one hour of admittance to the ICU. The
microbiology analysis of blood samples revealed MRSA.
The therapy was changed to daptomycin on 12 March
2012. After 30 doses of daptomycin intravenously based
on his glomerular filtrate rate (GFR), the patient was
discharged from the hospital on 18 April.
On 9 May 2012, 20 days after the last dose of daptomy-
cin, he returned to the hemodialysis department with a re-
spiratory syndrome. The chest computed tomography
demonstrated signs of pneumonia. Therefore, three sam-
ples of peripheral blood were sent to the hospital labora-
tory. Antibiotic therapy (vancomycin, meropenem and
trimethoprim-sulfamethoxazole) was initiated according
to the microbiology data. The vascular catheter was with-
drawn because there was free purulent secretion at the in-
sertion site. Once again, a new catheter was implanted, this
time, in the right femoral vein for hemodialysis therapy.
The new MRSA isolate from the blood samples
showed a multidrug resistance pattern. The isolate was
resistant to ciprofloxacin, rifampin, chloramphenicol,
clindamycin and erythromycin but showed susceptibil-
ity to linezolid, quinupristin-dalfopristin, tetracycline
and trimethoprim-sulfamethoxazole by the disk-diffusion
test. The minimum inhibitory concentration (MIC)
assessed by broth microdilution method showed MICs
of >256 μg/mL, 4 μg/mL and 8 μg/mL for oxacillin, vanco-
mycin and daptomycin, respectively. The SCCmec typing
[5], pulsed field gel electrophoresis [6] and multilocus se-
quence typing (MLST) [7] revealed that the isolate
belonged to the SCCmec II/USA100/ST5 lineage. After
3 months in hospital, the patient died from a hemorrhagic
stroke and pneumonia associated mechanical ventilation
due to Acinetobacter baumanni.
Discussion
Methicillin-resistant S. aureus (MRSA) infections are be-
coming more frequent and are less easily treated with the
current antibiotic agents. There is a high incidence of
catheter-related bloodstream-infections (CRBSI) caused by
MRSA among patients undergoing hemodialysis and the
mortality rates are also high [1,2]. Although vancomycin is
the mainstay treatment for MRSA complicated infections,
the experts observed failure of vancomycin therapy associ-
ated to high mortality rates have been observed whenMRSA isolates exhibits MIC ≥2 μg/mL [8]. According to
Clinical Practice Guidelines for the Diagnosis and Manage-
ment of CRBSI daptomycin is recommended when MRSA
isolates exhibit vancomycin MIC >2 μg/mL . In this study,
the MRSA isolate recovered from the blood of the patient
had a MIC =4 μg/ml to vancomycin, justifying the anti-
biotic therapy of daptomycin.
Clinical cases have shown decreasing susceptibility of
S. aureus to daptomycin due to antibiotic pressure exerted
by vancomycin, and vice versa [9,10]. Data from 30
MRSA isolates recovered from bloodstream infections
between 2011 and 2013 were evaluated by our group.
The results showed that among 13 isolates with a
vancomycin MIC =1 μg/ml, 85% showed daptomycin
MIC ≥1 μg/ml. Likewise, among 16 isolates with vanco-
mycin MIC ≥2 μg/ml 43.7% also presented MIC ≥2 μg/ml
for daptomycin (Table 1; data not published). Kirby et al.
[11] reported an infection by daptomycin-resistance S.
aureus from a catheter-related BSI in a hemodialysis pa-
tient. The authors confirmed that the MIC to daptomycin
of this isolate increased from 0.25 to 0.5 after nine months
of various schemes of vancomycin therapy, even though
the patient had never received daptomycin. After five
months of daptomycin therapy be started, the MIC value
to this drug increased to 62 μg/mL. In our case, after 30
doses of daptomycin, the resistance to this drug was de-
tected in the MRSA with MIC 4 μg/mL for vancomycin.
Nevertheless, resistance to daptomycin in S. aureus iso-
lates remains rare. A study conducted by a surveillance
program analyzed 49,000 S. aureus isolates collected from
around the world, between 2005 and 2008, and found only
53 (0.05%) daptomycin-resistant isolates. Only one was re-
covered in Latin American. However, Dabul & Camargo
[4] recently reported two daptomycin-resistant S. aureus
isolates in Brazil, collected from a catheter tip and a leg
abscess in different patients. Both the isolates were
methicillin-resistant and belonged to the SCCmec II/
USA100/ST5 lineage, the same profile found in this study.
This lineage has established itself in Brazilian hospitals
[12,13]. The genetic similarity found between the isolates
indicates a facility of this genotype to develop resistance
to daptomycin.
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Vancomycin and daptomycin resistance in S. aureus are
especially worrying in hemodialysis patients due to the
high incidence of CRBSI [1,2] which are frequently treated
with these antimicrobials. In this study we described the
CRBSI of a Brazilian patient caused by a daptomycin-
resistant MRSA belonging to a lineage already involved in
daptomycin-resistance in Brazil. Thus, our case high-
lights the careful management of BSI infections and
the importance of the judicious use of antimicrobials
due the possibility of daptomycin-resistance develop-
ing among S. aureus isolates.
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